A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...
The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...
Idiopathic pulmonary fibrosis (IPF) is when the lungs become scarred, and breathing becomes increasingly difficult. Damage to ...
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
News Medical on MSN2d
Fibrosis a prognostic biomarker for HER2-negative breast cancerThe most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback